Resmed Cdi
$31.79Change from previous close: +0.76%Absolute change: +$0.24
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- $44.71B
- Enterprise value
- $17.7B
- P/E (trailing 12 months)
- 21.2
- Forward P/E
- 16.5
- PEG
- 1.28
- Price/book
- 1.99
- Price/sales
- 7.91
- EV/EBITDA
- 8.45
- EV/revenue
- 3.13
Profitability and growth
- Gross margin
- 61.6%
- Operating margin
- 30.9%
- Net margin
- 26.9%
- ROE
- 24.3%
- ROA
- 14.0%
- Revenue growth (year over year)
- 8.6%
- Earnings growth (year over year)
- 2.4%
Financial health
- Total cash
- $1.47B
- Total debt
- $825.92M
- Debt/equity
- 0.13
- Current ratio
- 3.10
- Quick ratio
- 1.83
Dividends
- Annual dividend per share
- $0.38
- Dividend yield
- 1.2%
- Payout ratio
- 23.0%
- Ex-dividend date
- August 19, 2026
Analysts and estimates
- Average price target
- $40.77
- Median price target
- $40.49
- High price target
- $47.99
- Low price target
- $34.20
- Analysts with a price target
- 13
- Consensus
- Strong buy
- Forward EPS
- $1.93
- EPS estimate, current year
- $1.21
Shares and trading
- Beta
- 0.77
- Average volume
- 1.58M
- Shares outstanding
- 1.41B
- Float
- 573.45M
- Institutional ownership
- 9.5%
- Insider ownership
- 0.0%